BNN — BRAIN Biotech AG Income Statement
0.000.00%
- €51.12m
- €101.93m
- €55.50m
Annual income statement for BRAIN Biotech AG, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 39.1 | 39.2 | 50.3 | 56.2 | 55.5 |
Cost of Revenue | |||||
Gross Profit | 22 | 22.4 | 28.2 | 31 | 31.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 47.3 | 45.8 | 55.9 | 61.7 | 64.4 |
Operating Profit | -8.23 | -6.55 | -5.65 | -5.48 | -8.85 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.94 | -4.28 | -6.17 | -7.49 | -11 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.02 | -4.68 | -6.34 | -8.11 | -11.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -9.68 | -4.97 | -6.59 | -8.28 | -11.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.68 | -4.97 | -6.59 | -8.28 | -11.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.391 | -0.267 | -0.307 | -0.371 | -0.509 |
Dividends per Share |